Introduction
Annual reports
- Pfizer: 2006 - 2005 - 2004
- GSK: 2006 - 2005 - 2004 - 2003 - 2002
- Sanofi-Aventis: 2006 - 2005
- Novartis: 2006 - 2005 - 2004 - 2003 - 2002 - 2001 - 2000
- Johnson & Johnson: 2006 - 2005 - 2004 - 2003 - 2002 - 2001 - 2000
- AstraZeneca: 2006 - 2005 - 2004 - 2003 - 2002 - 2001(a)(b)
- Merck: 2006 - 2005 - 2004 - 2003
- Roche: 2005 - 2004 - 2003 - 2002 - 2001 - 2000
- Abbott: 2005 - 2004 - 2003
- BMS: 2005 - 2004 - 2003
- Eli Lilly: 2005 - 2004 - 2003 - 2002 - 2001 - 2000
- Amgen: 2005 - 2004 - 2003 - 2002 - 2001 - 2000
- Teva
Policies
Pfizer
- Policies on Business Conduct (Blue Book)
- Corporate Compliance Program
- Key Principles Guide
- Healthcare Law Compliance: The Pfizer White Guide
- 2005 Corporate Citizenship Report
- Practicing Ethical Sales and Marketing
- Advertising and Promotion
- Press release, Pfizer Announces Improvements to Consumer Advertising for Prescription Medicines (August 2005)
- Healthcare Law Compliance: The Pfizer White Guide
- Prescription Drug Advertising: Empowering Consumers Through Information, Economic Realities in Healthcare Policy, 2001; Vol. 2, Iss. 1
- Pharmaceutical Marketing and Promotion: Creating Access to Innovation Pfizer Inc, Economic Realities in Healthcare Policy>, 2003; Vol. 3, Iss. 1
- Risk Information in Print Advertisements, Pfizer comments to the US Food and Drug Administration in the matter of Disclosing Risk Information in Consumer-Directed Print Advertisements, May 7, 2004
- Direct to Consumer Promotional Communications, Pfizer comments to the US Food and Drug Administration in the matter of Consumer-Directed Promotion, December 1, 2003
- DTC Benefits Supported By a Strong Data Record
Merck
- Code of conduct
- Merck & Co., Inc. Comprehensive Compliance
- Corporate Responsibility 2004-2005 Report
- Policy on Direct-to-Consumer Advertising in the United States
- Policy on Importation of Medicines
- Policy on Prescription Drug Pricing
- Policy on Political Contributions
GSK
- GlaxoSmithKline Compliance Program – U.S. Operations
- GSK, GSK Public Policy on Pharmacovigilance
- Corporate Responsibility Report 2005
- GSK European Promotion of Medicines Code of 2007
- Employee Guide to Business Conduct
- Code of conduct
- Corporate Responsibility Report 2006
Novartis
- Code of Conduct
- Novartis Conflict of Interest Policy
- Policy on Corporate Citizenship
- Management of Corporate Citizenship guideline
- Novartis Promotional Practices Policy and Guidelines
- Bribery, Gifts and Entertainment Guideline
- Third Party Management Guideline
- Integrity and compliance at Novartis
- Novartis Third Party Code of Conduct
- Novartis guideline on human rights
- Novartis corporate governance document
- Novartis on complaint handling
- Novartis committment to the UN Global Compact
- Novartis sustainability reporting
- Novartis on responsible lobbying
- Novartis on ethical promotion of pharmaceuticals
- Novartis on patient group interaction and support
Sanofi - Aventis
Abbott
- Code of Business Conduct
- Comprehensive Ethics and Compliance Program Declaration – State of California
- Supplier Code of Conduct
- Global Citizenship Report 2005
- Global Citizenship Report 2004
- Global Citizenship Report 2003
AstraZeneca
Bristol - Meyers - Squibb
Roche
- Corporate Principles
- Integrity in Business
- Behaviour in Competition
- Key Business Partners
- Roche Guidelines on Dealing with Suppliers and Service Providers
- Insider Policy
- Marketing Practices Employment Policy Communication Policy
- Safety, Health & Environmental Protection
- Working with patient groups: Good practice guidelines
- Patient organisations to which Roche provides financial support in the UK
Lilly
- Code of business conduct - red book
- Policy on Ethical Marketing and Use
- The Red Book
- Code of Ethical Conduct for Eli Lilly and Company Financial Management
- Public policy page
- Access to medicines page
- Corporate Citizenship Report 2005-2006 - 2006-2007
- Corporate Responsibility - Report 2003
Industry overview
- PhRMA Industry Profile: 2007 - 2006 - 2005 -2004 -
- PhRMA, Annual Report: 2007 - 2006-2007 - 2005 -2006
- EFPIA, The Pharmaceutical Industry in Figures: 2007 - 2006 - 2005 - 2003 - 2002 - 2001 - 2000
- Interpharma, Plaut Economics, Importance croissante de l’industrie pharmaceutique pour la Suisse (août 2005)
- Interpharma: Le marché du médicament en Suisse: 2007 - 2005 - 2004
- Interpharma, La santé publique en Suisse: 2007 - 2006 - 2005 - 2003 -
- Interpharma, BAK, Importance de l'industrie chimique et pharmaceutique pour l'économie suisse